Compare JEF & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JEF | ICLR |
|---|---|---|
| Founded | 1968 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 9.3B |
| IPO Year | 2013 | 2001 |
| Metric | JEF | ICLR |
|---|---|---|
| Price | $61.44 | $146.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $61.40 | ★ $178.62 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 03-25-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $10,823,677,000.00 | N/A |
| Revenue This Year | $13.23 | N/A |
| Revenue Next Year | $10.25 | N/A |
| P/E Ratio | $85.24 | ★ $12.91 |
| Revenue Growth | ★ 2.93 | N/A |
| 52 Week Low | $35.53 | $66.57 |
| 52 Week High | $71.04 | $211.00 |
| Indicator | JEF | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 77.67 | 63.32 |
| Support Level | $59.39 | $99.11 |
| Resistance Level | $64.39 | $188.03 |
| Average True Range (ATR) | 1.77 | 8.29 |
| MACD | 0.60 | 1.04 |
| Stochastic Oscillator | 90.84 | 77.73 |
Jefferies Financial Group is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since merging, Jefferies became the core of the combined business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.